Table 1.
Characteristics of the study population
| Characteristics | Total population (n=62) |
| Demographics | |
| Age (years) (mean (SD)) | 67.3 (12.8) |
| Male (n (%)) | 53 (85.5) |
| Body mass index (kg/m2) (median (IQR)) | 27.1 (26.1 to 30.9) |
| Daily alcohol >30 g (n (%)) | 9 (15.8) |
| Excessive sugar-sweetened beverage intake (n (%)) | 1 (1.6) |
| Purine-rich diet (n (%)) | 10 (17.9) |
| Gout characteristics | |
| Symptom duration (years) (median (IQR)) | 10 (3–16) |
| Subcutaneous tophi (n (%)) | 26 (41.9) |
| Number of flares in past 6 months (median (IQR)) | 2 (1–3) |
| Urate-lowering therapy naive (n (%)) | 41 (66.1) |
| Comorbidities | |
| History of urolithiasis (n (%)) | 12 (19.7) |
| Hypertension (n (%)) | 45 (72.6) |
| Chronic heart failure (n (%)) | 18 (29.0) |
| History of myocardial infarction (n (%)) | 11 (17.7) |
| Coronary heart disease (n (%)) | 13 (21.0) |
| Cardiovascular disease | 26 (41.9) |
| History of stroke (n (%)) | 2 (3.2) |
| Dyslipidaemia (n (%)) | 29 (46.8) |
| Diabetes mellitus (n (%)) | 18 (29.0) |
| Obstructive sleep apnoea (n (%)) | 7 (11.3) |
| Treatments | |
| Diuretics (n (%)) | 19 (30.6) |
| Lipid-lowering drugs (n (%)) | 30 (48.4) |
| Antihypertensive drugs (n (%)) | 44 (71.0) |
| Antiplatelet/anticoagulants | 30 (48.4) |
| Laboratory findings | |
| Serum urate level (mg/dL) (median (IQR)) | 8.4 (6.6–9.9) |
| Estimated glomerular filtration rate <60 mL/min/1.73 m2 (n (%)) | 14 (24.6) |
| Dual-energy CT volumes of MSU crystal deposits | |
| Feet (cm3) (median (IQR)) | 0.5 (0.2–1.9) |
| Knees (cm3) (median (IQR)) | 0.4 (0.1–1.2) |
| Total (cm3) (median (IQR)) | 1 (0.4–2.7) |
MSU, monosodium urate.